Role of erythropoietin in the treatment of Alzheimer’s disease: the story so far

Abstract

This review aims to explore the potential of Erythropoietin, a glycopeptide hormone, as a treatment option for Alzheimer’s Disease, which is the commonest cause of dementia. Despite years of focus and research, therapeutic options for Alzheimer’s disease are not yet completely satisfactory. And as people age, they are likely to develop Alzheimer’s Disease, further pressuring the healthcare system. So, it is definite to develop treatment options that meet superior outcomes with minimal negative effects. A comprehensive review of the literature was conducted in PubMed and Google Scholar using a combination of keywords, including Alzheimer’s Disease, Dementia, Erythropoietin, and Neuroprotection. Search results were assessed for relevance before using the data for this study. The beneficial implications of erythropoietin as a therapeutic option have been explored, along with the side effects and mechanisms of erythropoietin in Alzheimer’s Disease. Overall, our review indicates that erythropoietin presents a promising avenue for mitigating the progression of Alzheimer’s Disease, with minimal associated side effects.